Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDC00006

Target Information
NameAurora kinase A    
Type of targetClinical trial target    
Aurora-related kinase 1    
Aurora/IPL1-related kinase 1    
Breast tumor-amplified kinase    
Serine/threonine kinase 15    
Serine/threonine-protein kinase 6    
DiseaseColorectal Cancer    [1][2]
Lymphoma, Unspecified    [3][4][5]
Solid tumors    [6][7][8]
Drug(s)AZD1152Phase IIAcute Myeloid Leukemia, Haematological malignancies[9]
ENMD-2076Phase IIOvarian Cancer, Fallopian Cancer, Peritoneal Cancer[10]
MLN8237Phase IIAcute myelogenous leukemia, High-risk myelodysplastic syndrome and Ovarian cancer[11]
PHA-739358Phase IICML that relapsed after imatinib or BCR¨CABL-targeted therapy; Metastatic Hormone Refractory Prostate Cancer (MHRPC)[10]
AT-9283Phase I/IIAdult solid tumours, NHL, AML, ALL, CML, MDS and myelofibrosis[10]
AZD1152Phase I/IIMyeloid Leukemia[9]
MLN8237Phase I/IIPaediatric solid tumours or ALL[11]
SNS-314Phase I completedSolid Tumors[12][6][7][8][12]
AT9283Phase ILeukemia, Myeloid[13][14]
MK-5108Phase ICancer; Neoplasms; Tumors[15][16]
MLN8237Phase IAdvanced solid tumours and haematological malignancies[11]
PF-03814735Phase IAdvanced solid tumours[10]
R763Phase IHaematological Malignancies[17]
VX-689Phase ICancer; Neoplasms; Tumors[10]
CYC-116Terminated in Phase IAdvanced solid tumours[10]
CYC116Terminated in Phase ISolid Tumors[18]
MLN8054Terminated in Phase ISolid tumours[19][20][21]
MLN8054Terminated in Phase IAdvanced malignancies[19][20][21]
SU-6668DiscontinuedAdvanced solid tumours[19][22]
VX-680Terminated in Phase IILeukemia[19][1]
VX-680Terminated in Phase IChronic Myelogenous Leukemia; Leukemia; Lymphoblastic, Acute, Philadelphia-Positive[19][1]
EC NumberEC
UniProt IDO14965
PDB Structure1MQ4; 1MUO; 1OL5; 1OL6; 1OL7; 2BMC; 2C6D; 2C6E.    
Target ValidationClick to Find Target Validation Information.    
Inhibitor2- (1H-pyrazol-3-yl)-1H-benzimidazole[23]
4- (1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine[24]
AZD-1152-HQPA,   Barasertib[26]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Essential roles of mTOR/Akt pathway in Aurora-A cell transformation. Int J Biol Sci. 2009 Jun 19;5(5):444-50. To Reference
Ref 2Research Progress on Aurora Kinase Inhibitor MK-0457 in Therapy for Some Hematological Malignancies-Review.. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):810-5. To Reference
Ref 3Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther. 2009 Jul;8(7):2046-56. Epub 2009 Jul 7. To Reference
Ref 4Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks. J Biol Chem. 2009 Jun 5;284(23):15880-93. Epub 2009 Apr 9. To Reference
Ref 5The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle. 2009 Mar 15;8(6):876-88. Epub 2009 Mar 21. To Reference
Ref 6The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009 Apr;8(4):930-9. To Reference
Ref 7Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. To Reference
Ref 8Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1409-12. Epub 2009 Jan 19. To Reference
Ref 9AstraZeneca. Product Development Pipeline. January 29 2009. To Reference
Ref 10Nat Rev Drug Discov. 2009 Jul;8(7):547-66.Cell cycle kinases as therapeutic targets for cancer. To Reference
Ref 11Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553 To Reference
Ref 12SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2009 Aug 1. [Epub ahead of print] To Reference
Ref 13Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle. 2009 Jun 15;8(12):1921-9. Epub 2009 Jun 15. To Reference
Ref 14J Med Chem. 2009 Jan 22;52(2):379-88.Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. To Reference
Ref 15Merck. Product Development Pipeline. July 15 2009. To Reference
Ref 16Merck. Report of Merck. 2009. To Reference
Ref 17J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. To Reference
Ref 18Report from Cyclacel Pharmaceuticals. Cyclacel Limited. April 2008 To Reference
Ref 19A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 20Takeda. Product Development Pipeline. July 31 2009. To Reference
Ref 21MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol. 2007 Jun;27(12):4513-25. Epub 2007 Apr 16. To Reference
Ref 22Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res. 2005 Sep 1;11(17):6240-6. To Reference
Ref 23Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. To Reference
Ref 24Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5. Epub 2010 Mar 1.Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. To Reference
Ref 25J Med Chem. 2007 Aug 23;50(17):4027-37. Epub 2007 Aug 1.An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. To Reference
Ref 26J Med Chem. 2007 May 3;50(9):2213-24. Epub 2007 Mar 21.Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. To Reference
Ref 27Nucleic Acids Res. 2011 January; 39(Database issue): D1035¨CD1041. DrugBank 3.0: a comprehensive resource for ¡®Omics¡¯ research on drugs To Reference
Ref 28J Med Chem. 2010 May 27;53(10):3973-4001.Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. To Reference
Ref 29J Med Chem. 2005 Apr 21;48(8):3080-4.Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. To Reference
Ref 30Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 31J Med Chem. 2006 Aug 10;49(16):4805-8.Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543